Aldeyra Therapeutics (ALDX) news
Recent news
Aldeyra Therapeutics - to request FDA Type D meeting on NDA of Reproxalap resubmission by end of Q3 2026 - SEC filing
AInvest Wire · Jul 15, 2026Aldeyra: intends to request a Type D meeting with FDA
AInvest Wire · Jul 15, 2026Aldeyra Therapeutics received minutes type A meeting with FDA
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) has received minutes from a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for reproxalap, an investigational treatment for dry eye disease. The meeting followed a Complete Response Letter (CRL)…
AInvest Wire · Jul 15, 2026Aldeyra Therapeutics names Darlene Deptula-Hicks to board
Aldeyra Therapeutics has announced the appointment of Darlene Deptula-Hicks, MBA, as a Non-Executive Director of its Board of Directors. The addition of Deptula-Hicks, a seasoned financial executive with extensive experience in the life sciences sector, reflects the company’s strategic focus on…
AInvest Wire · Jun 10, 2026Aldeyra Therapeutics reports advancement of RASP platform in systemic and retinal inflammatory diseases
Aldeyra Therapeutics reports advancement of RASP platform in systemic and retinal inflammatory diseases Aldeyra Therapeutics, a biotechnology company focusing on immune-mediated diseases, has announced significant advancements in its RASP (Reactive Amide Synthase Probe) modulator platform. These…
AInvest Wire · Jan 4, 2024Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.